Lowering Prescription Drug Costs and Extending Community Health Centers and Other Public Health Priorities Act

Bill: 116-hr-2700
Sponsor: Rep. Burgess, Michael C. [R-TX-26]
Introduced: 2019-05-14 in the House
Policy area: Health
Subjects: Administrative law and regulatory procedures
Appropriations
Child health
Civil actions and liability
Competition and antitrust
Consumer affairs
Digestive and metabolic diseases
Drug safety, medical device, and laboratory regulation
Education programs funding
Family planning and birth control
Federal Trade Commission (FTC)
Health care costs and insurance
Health care coverage and access
Health facilities and institutions
Health personnel
Health programs administration and funding
Health promotion and preventive care
Indian social and development programs
Inflation and prices
Judicial review and appeals
Licensing and registrations
Marketing and advertising
Medical education
Medical research
Minority health
National and community service
Prescription drugs
Product development and innovation
Sex and reproductive health
Social work, volunteer service, charitable organizations

Summary:
action_date: 2019-05-14
text: 

Lowering Prescription Drug Costs and Extending Community Health Centers and Other Public Health Priorities Act 

 
This bill addresses prescription drugs and extends several health care, research, and workforce programs.
 
Currently, a generic drug manufacturer is awarded 180 days of exclusivity on the market if it is the first applicant to file an application with the Food and Drug Administration (FDA), and the exclusivity period begins upon the first applicant's commercial marketing. The bill authorizes the FDAto approve a subsequent generic drug application prior to the first applicant's first date of commercial marketing if certain conditions are met. 

 
The bill prohibits a brand-name, generic, or biosimilar drug manufacturer from entering into certain agreements to resolve or settle a patent infringement claim in connection with the sale of a drug or biological product. Such an agreement, with specified exclusions, is a violation of the bill if the filer of the subsequent generic application receives something of value and agrees to limit or forego research, development, manufacturing, marketing, or sales of the generic drug or biological product.
 
The developer of a drug or biological product, such as a generic or biosimilar version of a drug, may bring a civil action against the license holder of an approved drug if the holder has declined to make available sufficient quantities of the approved drug for the developer's testing.
 
The bill also extends several health care, research, and workforce programs, including the National Health Service Corps, through FY2020.

 


Legislative actions:
action_date: 2019-06-26
text: Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
action_date: 2019-06-26
text: Referred to the Subcommittee on Courts, Intellectual Property, and the Internet.
action_date: 2019-05-15
text: Referred to the Subcommittee on Health.
action_date: 2019-05-14
text: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
action_date: 2019-05-14
text: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
action_date: 2019-05-14
text: Introduced in House
action_date: 2019-05-14
text: Introduced in House